PROTOKOLwiki
COMPOUNDS / AMINO ACID / AGMATINE SULFATE
AMINO ACID

AGMATINE SULFATE

LOW RISK
BEST FOR:Neuropathic Pain●●●●●●●○○○7/10
AGMATINE SULFATE · AGMATINE · DECARBOXYLATED ARGININE · 1-AMINO-4-GUANIDINOBUTANE · 4-AMINOBUTYLGUANIDINE · G-AGMATINE · AGMASET
Amino AcidNootropicNeuroprotectiveAnalgesicNitric Oxide Modulator

Decarboxylated arginine derivative with neuroprotective, analgesic, and nootropic properties; used for neuropathic pain and cognitive support.

ROUTE / DOSAGE
LOW500mg
STANDARD1000-2000mg
HIGH2670-3560mg
Note: Clinical trials used 2.67g/day for neuropathic pain; nootropic doses typically lower
CYCLE
Daily use up to 21 days in clinical trials cycling not required but long-term data limited
BIOAVAILABILITY
Moderate oral crosses blood-brain barrier with brain accumulation demonstrated in animal models
ACTIVE DURATION
4-6h (subjective)
STORAGE
Room temperature dry away from light hygroscopic - keep sealed
HALF-LIFE
2-4h (plasma)
DURATION BREAKDOWN
Total4-8h
Onset30-60min
Come up30-60min
Peak1-3h
Offset2-4h
After effects2-4h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Reduced neuropathic pain
Neuroprotection
Mild blood pressure reduction
Anti-inflammatory action
Improved mood and cognition
Reduced gastric ulceration risk
§ 02 — RISKS
Mild-to-moderate GI distress (diarrhea, nausea) at high doses (>3.5g/day)
Mild blood pressure reduction - caution with antihypertensives
Slight weight reduction at high chronic doses
Limited long-term human safety data beyond 21 days
Potential modulation of polyamine metabolism with chronic use
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Clinical evidence supports agmatine sulfate's efficacy in reducing neuropathic pain associated with small fiber neuropathy and lumbar disc radiculopathy, with significant pain reduction demonstrated in open-label and randomized placebo-controlled trials. Preclinical studies confirm neuroprotective, anti-inflammatory, and anti-metastatic properties. Safety data from mutagenicity and genotoxicity studies are reassuring, and both acute and sub-chronic oral dosing in animal models showed good tolerability. However, human clinical evidence remains limited to small sample sizes and short treatment durations (up to 21 days), and larger randomized controlled trials are needed to confirm efficacy and long-term safety.

§ 06 — SOURCES
[1]
Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy
pubmed.ncbi.nlm.nih.gov ↗
[2]
Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies
pubmed.ncbi.nlm.nih.gov ↗
[3]
Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate
pubmed.ncbi.nlm.nih.gov ↗
[4]
Evidence for oral agmatine sulfate safety--a 95-day high dosage pilot study with rats
pubmed.ncbi.nlm.nih.gov ↗
[5]
Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines
pubmed.ncbi.nlm.nih.gov ↗
[6]
Effect of Agmatine Sulfate on Modulation of Matrix Metalloproteinases via PI3K/Akt-1 in HT1080 Cells
pubmed.ncbi.nlm.nih.gov ↗
[7]
Agmatine Administration Effects on Equine Gastric Ulceration and Lameness
pubmed.ncbi.nlm.nih.gov ↗
[8]
Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT